Most valuable unpartnered assets reveal a changing of the guard
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
Biogen’s Alzheimer’s hope tops the sector’s most valuable pipeline projects
The lack of clinical progress in Alzheimer's has not put analysts off valuing aducanumab at $10bn.
Calling time on biotech’s shady stock-promotion schemes
The US regulator has come down surprisingly hard on biotech stock promotion schemes.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.